3.25BMarket Cap
LossP/E TTM
NewAmsterdam Pharma Company NV
Key Figures
28.370Open
28.760High
956.63KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.82%Turnover Ratio
28.460Prev. Close
27.310Low
20.18MTurnover
LossP/E Static
4.87P/B
0.00%Div Yield TTM
-27.43%ROA
42.20552wk High
1.02Volume Ratio
-241.60MNet Profit
116.64MShares
-1.7787EPS TTM
0.08Beta
-29.49%ROE
16.95052wk Low
5.09%Amplitude
100.00%Gross Margin
3.25BMarket Cap
-5.33Reward/Risk
3.46%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
NewAmsterdam Pharma Company NV's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 34 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 51.93.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
NewAmsterdam Pharma Company NV's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
NewAmsterdam Pharma Company NV Highlights
StrengthsRisks
NewAmsterdam Pharma Company NV News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
NewAmsterdam Pharma Company NV
NAMS
17
Ionis Pharmaceuticals Inc
IONS
26
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
NewAmsterdam Pharma Company NV Info
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
Ticker SymbolNAMS
CompanyNewAmsterdam Pharma Company NV
CEODavidson (Michael Harvey)
Websitehttps://ir.newamsterdampharma.com/
Shareholders
FAQs
What is the current price of NewAmsterdam Pharma Company NV (NAMS)?
The current price of NewAmsterdam Pharma Company NV (NAMS) is 27.79.
What is the symbol of NewAmsterdam Pharma Company NV?
The ticker symbol of NewAmsterdam Pharma Company NV is NAMS.
What is the 52-week high of NewAmsterdam Pharma Company NV?
The 52-week high of NewAmsterdam Pharma Company NV is 42.20.
What is the 52-week low of NewAmsterdam Pharma Company NV?
The 52-week low of NewAmsterdam Pharma Company NV is 16.95.
What is the market capitalization of NewAmsterdam Pharma Company NV?
The market capitalization of NewAmsterdam Pharma Company NV is 3.24B.
Is NewAmsterdam Pharma Company NV (NAMS) currently rated as Buy, Hold, or Sell?
According to analysts, NewAmsterdam Pharma Company NV (NAMS) has an overall rating of Buy, with a price target of 51.93.
What is the Earnings Per Share (EPS TTM) of NewAmsterdam Pharma Company NV (NAMS)?
The Earnings Per Share (EPS TTM) of NewAmsterdam Pharma Company NV (NAMS) is -1.72.
